Merus N.V. CS (MRUS) 10.65 $MRUS Merus N.V. : M
Post# of 273323
Posted On: 09/23/2016 5:13:08 AM
Merus N.V. CS (MRUS) 10.65 $MRUS
Merus N.V. : Merus to Participate in Upcoming Investor Conferences
Globe Newswire - Wed Aug 31, 6:00AM CDT
UTRECHT, The Netherlands, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences:
MRUS: 10.65 (-0.01)
Merus to Participate in Upcoming Investor Conferences
GlobeNewswire - Wed Aug 31, 6:00AM CDT
Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences:
MRUS: 10.65 (-0.01)
Merus to Present at the 2016 Wedbush PacGrow Healthcare Conference
Globe Newswire - Wed Aug 10, 6:00AM CDT
UTRECHT, The Netherlands, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17 at 2:30 PM ET at the Le Parker Meridien in New York City.
MRUS: 10.65 (-0.01)
Merus Announces Second Quarter 2016 Financial Results and Reviews Recent Clinical Progress and Corporate Developments
Globe Newswire - Mon Aug 08, 6:00AM CDT
UTRECHT, The Netherlands, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2016 and provided a review of recent accomplishments and clinical development plans.
MRUS: 10.65 (-0.01)
Merus N.V. Signs Commercial Multi-Product License for ProBioGen's GlymaxX(R) ADCC Enhancement Technology
Globe Newswire - Wed Jun 01, 6:45AM CDT
Bispecific Cancer Antibody Pipeline Optimized by GlymaxX(R) Manufacturing Technology
MRUS: 10.65 (-0.01)
Merus N.V. Announces Closing of Partial Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Tue May 31, 6:00AM CDT
Merus N.V. ("Merus"
(Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of a partial exercise of the over-allotment option by the underwriters of its previously announced initial public offering in the amount of an additional 639,926 common shares at the initial public offering price of $10.00 per share. The sale of the additional shares closed on May 26, 2016, bringing the total number of common shares sold by Merus in its initial public offering to 6,139,926. Including the proceeds from the sale of the additional shares, the total net proceeds, after deducting the underwriting discounts and commissions and estimated offering expenses, to Merus from its initial public offering are approximately $53.3 million.
MRUS: 10.65 (-0.01)
Merus N.V. : Merus N.V. Announces Closing of Initial Public Offering
Globe Newswire - Tue May 24, 1:44PM CDT
UTRECHT, the Netherlands, May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. ("Merus" (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol "MRUS" on May 19, 2016. All of the common shares in the offering were offered by Merus. The net proceeds to Merus from the sale of shares in the offering are estimated to be approximately $47.3 million, after deducting the underwriting discounts and commissions and estimated offering expenses.
MRUS: 10.65 (-0.01)
Merus N.V. Announces Closing of Initial Public Offering
GlobeNewswire - Tue May 24, 1:17PM CDT
Merus N.V. ("Merus" (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol "MRUS" on May 19, 2016. All of the common shares in the offering were offered by Merus. The net proceeds to Merus from the sale of shares in the offering are estimated to be approximately $47.3 million, after deducting the underwriting discounts and commissions and estimated offering expenses.
MRUS: 10.65 (-0.01)
Merus N.V. (Nasdaq: MRUS) to Ring The Nasdaq Stock Market Closing Bell in celebration of IPO
GlobeNewswire - Thu May 19, 5:00AM CDT
What:
MRUS: 10.65 (-0.01), NDAQ: 70.44 (-0.23)
Merus N.V. : Merus to Participate in Upcoming Investor Conferences
Globe Newswire - Wed Aug 31, 6:00AM CDT
UTRECHT, The Netherlands, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences:
MRUS: 10.65 (-0.01)
Merus to Participate in Upcoming Investor Conferences
GlobeNewswire - Wed Aug 31, 6:00AM CDT
Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences:
MRUS: 10.65 (-0.01)
Merus to Present at the 2016 Wedbush PacGrow Healthcare Conference
Globe Newswire - Wed Aug 10, 6:00AM CDT
UTRECHT, The Netherlands, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17 at 2:30 PM ET at the Le Parker Meridien in New York City.
MRUS: 10.65 (-0.01)
Merus Announces Second Quarter 2016 Financial Results and Reviews Recent Clinical Progress and Corporate Developments
Globe Newswire - Mon Aug 08, 6:00AM CDT
UTRECHT, The Netherlands, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2016 and provided a review of recent accomplishments and clinical development plans.
MRUS: 10.65 (-0.01)
Merus N.V. Signs Commercial Multi-Product License for ProBioGen's GlymaxX(R) ADCC Enhancement Technology
Globe Newswire - Wed Jun 01, 6:45AM CDT
Bispecific Cancer Antibody Pipeline Optimized by GlymaxX(R) Manufacturing Technology
MRUS: 10.65 (-0.01)
Merus N.V. Announces Closing of Partial Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Tue May 31, 6:00AM CDT
Merus N.V. ("Merus"
(Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of a partial exercise of the over-allotment option by the underwriters of its previously announced initial public offering in the amount of an additional 639,926 common shares at the initial public offering price of $10.00 per share. The sale of the additional shares closed on May 26, 2016, bringing the total number of common shares sold by Merus in its initial public offering to 6,139,926. Including the proceeds from the sale of the additional shares, the total net proceeds, after deducting the underwriting discounts and commissions and estimated offering expenses, to Merus from its initial public offering are approximately $53.3 million. MRUS: 10.65 (-0.01)
Merus N.V. : Merus N.V. Announces Closing of Initial Public Offering
Globe Newswire - Tue May 24, 1:44PM CDT
UTRECHT, the Netherlands, May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. ("Merus"
(Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol "MRUS" on May 19, 2016. All of the common shares in the offering were offered by Merus. The net proceeds to Merus from the sale of shares in the offering are estimated to be approximately $47.3 million, after deducting the underwriting discounts and commissions and estimated offering expenses. MRUS: 10.65 (-0.01)
Merus N.V. Announces Closing of Initial Public Offering
GlobeNewswire - Tue May 24, 1:17PM CDT
Merus N.V. ("Merus"
(Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol "MRUS" on May 19, 2016. All of the common shares in the offering were offered by Merus. The net proceeds to Merus from the sale of shares in the offering are estimated to be approximately $47.3 million, after deducting the underwriting discounts and commissions and estimated offering expenses. MRUS: 10.65 (-0.01)
Merus N.V. (Nasdaq: MRUS) to Ring The Nasdaq Stock Market Closing Bell in celebration of IPO
GlobeNewswire - Thu May 19, 5:00AM CDT
What:
MRUS: 10.65 (-0.01), NDAQ: 70.44 (-0.23)
(0)
(0)